Fact Meets Function

KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling.

KPV, an endogenous tripeptide, suppresses adipocyte differentiation and lipid accumulation in vitro by reducing ROS production and modulating AKT/mTOR/PPARγ signaling pathways. In a high-fat diet obesity mouse model, oral KPV administration reduced body weight gain, adipose tissue expansion, and obesity-related dyslipidemia including elevated cholesterol. These findings demonstrate KPV’s potential as a peptide-based therapeutic for obesity prevention and metabolic management, with clear mechanisms of action relevant to practitioner-prescribed metabolic support.

KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling. Read Post »

Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells.

A new in vitro study demonstrates that KPV, one of Annular’s peptide compounds, significantly reduces fat accumulation in liver cells exposed to oleic acid, a model for non-alcoholic fatty liver disease (NAFLD). The research shows KPV works by reducing oxidative stress and regulating key fat-production pathways, specifically targeting the PPAR gamma pathway that controls fatty acid synthesis. At 100 μg/mL concentration, KPV prevented liver cell damage and normalized fat metabolism without toxicity. This provides mechanistic evidence for KPV’s potential therapeutic role in treating hepatic steatosis, the early stage of NAFLD.

Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells. Read Post »

Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers.

Research Summary

Researchers developed inflammation-triggered self-immolative conjugates designed to deliver peptides orally by protecting them from gastrointestinal degradation and enhancing intestinal absorption in an animal model. The conjugates were engineered to release their peptide payload specifically in response to inflammatory markers present in the gastrointestinal tract, potentially enabling oral administration of peptides like KPV that are normally destroyed by stomach acid and digestive enzymes. This is an animal model study published in *Science Advances*.

Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. Read Post »

Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease.

This review article examines host defense peptides (HDPs), particularly KPV, as potential therapeutic agents for inflammatory bowel disease (IBD), discussing their mechanisms of action in modulating immune responses and reducing intestinal inflammation. The authors synthesize evidence from multiple study types—including in vitro, animal models, and human clinical investigations—to evaluate HDPs as a novel drug development strategy for IBD management. The evidence level is review article, which synthesizes findings across human clinical, animal model, and in vitro studies rather than presenting original research data.

Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease. Read Post »

Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway.

Researchers investigated how a lysine-proline-valine (KPV) peptide affects skin cells exposed to fine dust (PM2.5), examining its effects on cell death, inflammation, and underlying cellular pathways. The peptide reduced fine dust-induced keratinocyte apoptosis and inflammatory markers by decreasing oxidative stress and suppressing MAPK/NF-κB signaling pathways. **Evidence level: Human clinical study.**

Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Read Post »

Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review.

This review article examined the current evidence on tripeptides, particularly KPV (lysine-proline-valine), in wound healing and skin regeneration by synthesizing findings from multiple studies across different research models. The review found that tripeptides demonstrate anti-inflammatory and tissue-regenerative properties through various mechanisms, with evidence spanning in vitro studies, animal models, and limited human clinical applications. This is a **review article** synthesizing existing literature rather than primary research evidence.

Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review. Read Post »

KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy.

Researchers investigated carrier-free nanoparticles formed by self-assembly of KPV (a tripeptide) and RAPA (rapamycin) as a potential therapeutic approach for vascular calcification in an in vitro study. The findings demonstrated that these self-assembled nanodrugs effectively inhibited calcification markers in cell-based models without requiring synthetic delivery vehicles. This is an in vitro evidence level study and does not provide human clinical data.

KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy. Read Post »

A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment.

This preclinical study evaluated a nanoparticle delivery platform designed to promote mucosal healing and modulate immune responses in inflammatory bowel disease models. The research demonstrated that the nanoparticle formulation containing KPV (a tripeptide) enhanced intestinal barrier function and reduced inflammatory markers in laboratory and animal model systems. This represents early-stage evidence (animal model/in vitro) requiring further human clinical testing before any therapeutic application can be established.

A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. Read Post »

PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS.

Researchers developed a nanodrug delivery system that combines an anti-inflammatory peptide (KPV) with an immunosuppressant drug, designed to target PepT1 transporters in the intestine for treatment of colitis in a mouse model (Evidence level: Animal Model). In DSS-induced colitis models representing both acute and chronic disease, the targeted nanodrug demonstrated improved efficacy compared to free drug components, reducing inflammation and improving disease markers. This work represents a proof-of-concept for peptide-immunosuppressant co-assembly as a targeted delivery strategy, though translation to human clinical use remains to be determined.

PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS. Read Post »

The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials.

This review article examines the melanocortin system’s role in inflammatory bowel disease (IBD) pathogenesis, exploring how melanocortin receptors and their peptide ligands—including the tripeptide KPV—modulate intestinal inflammation through immune cell regulation and barrier function (review of human clinical, animal model, and in vitro evidence). The authors discuss mechanisms by which melanocortin signaling reduces pro-inflammatory cytokine production and promotes mucosal healing, alongside current understanding of therapeutic applications in IBD management. The evidence level is mixed, synthesizing findings from human clinical studies, animal models, and in vitro experiments to characterize the melanocortin system’s therapeutic potential.

The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials. Read Post »

A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.

Researchers developed a double-network hydrogel designed to deliver KPV (a tripeptide derived from α-melanocyte-stimulating hormone) to the colon in an animal model of inflammatory bowel disease, demonstrating that the hydrogel improved markers of mucosal barrier function and reduced inflammation in inflamed colon tissue. The hydrogel formulation was engineered to provide sustained KPV release and enhanced adhesion to the intestinal mucosa compared to free KPV alone. **Evidence level: Animal model**

A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Read Post »

Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats.

This animal model study evaluated a self-cross-linked hydrogel delivery system combining cysteamine-grafted γ-polyglutamic acid with the tripeptide KPV in rats with TNBS-induced ulcerative colitis. The hydrogel formulation demonstrated improved stability of the KPV tripeptide and showed alleviating effects on colitis markers in the rat model. This represents preclinical research requiring further development before clinical translation.

Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. Read Post »

Shopping Cart
Scroll to Top